Antineoplastic Combined Chemotherapy Protocols
"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
| Descriptor ID |
D000971
|
| MeSH Number(s) |
E02.183.750.500 E02.319.077.500 E02.319.310.037
|
| Concept/Terms |
Antineoplastic Combined Chemotherapy Protocols- Antineoplastic Combined Chemotherapy Protocols
- Combined Antineoplastic Agents
- Antineoplastic Agents, Combined
- Agent, Combined Antineoplastic
- Agents, Combined Antineoplastic
- Antineoplastic Agent, Combined
- Combined Antineoplastic Agent
- Antineoplastic Combined Chemotherapy Regimens
- Drug Combinations, Antineoplastic
- Anticancer Drug Combinations
- Anticancer Drug Combination
- Drug Combination, Anticancer
- Drug Combinations, Anticancer
- Antineoplastic Drug Combinations
- Antineoplastic Drug Combination
- Combinations, Antineoplastic Drug
- Drug Combination, Antineoplastic
Antineoplastic Chemotherapy Protocols- Antineoplastic Chemotherapy Protocols
- Antineoplastic Chemotherapy Protocol
- Chemotherapy Protocol, Antineoplastic
- Protocol, Antineoplastic Chemotherapy
- Protocols, Antineoplastic Chemotherapy
- Cancer Chemotherapy Protocols
- Cancer Chemotherapy Protocol
- Chemotherapy Protocol, Cancer
- Chemotherapy Protocols, Cancer
- Protocol, Cancer Chemotherapy
- Protocols, Cancer Chemotherapy
- Chemotherapy Protocols, Antineoplastic
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".
This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in this website by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 9 | 3 | 12 |
| 1996 | 10 | 4 | 14 |
| 1997 | 7 | 1 | 8 |
| 1998 | 12 | 3 | 15 |
| 1999 | 9 | 3 | 12 |
| 2000 | 8 | 3 | 11 |
| 2001 | 5 | 3 | 8 |
| 2002 | 8 | 7 | 15 |
| 2003 | 8 | 11 | 19 |
| 2004 | 7 | 8 | 15 |
| 2005 | 11 | 6 | 17 |
| 2006 | 14 | 7 | 21 |
| 2007 | 16 | 5 | 21 |
| 2008 | 24 | 8 | 32 |
| 2009 | 19 | 8 | 27 |
| 2010 | 19 | 11 | 30 |
| 2011 | 19 | 13 | 32 |
| 2012 | 15 | 6 | 21 |
| 2013 | 22 | 5 | 27 |
| 2014 | 31 | 12 | 43 |
| 2015 | 25 | 14 | 39 |
| 2016 | 13 | 15 | 28 |
| 2017 | 22 | 16 | 38 |
| 2018 | 34 | 17 | 51 |
| 2019 | 30 | 12 | 42 |
| 2020 | 25 | 18 | 43 |
| 2021 | 16 | 26 | 42 |
| 2022 | 9 | 34 | 43 |
| 2023 | 3 | 37 | 40 |
| 2024 | 20 | 24 | 44 |
| 2025 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
Pediatric relapsed/refractory ALK-positive anaplastic large cell lymphoma treatment and outcomes in the targeted-drug era. Blood Adv. 2025 Mar 25; 9(6):1356-1365.
-
How I treat patients with AML using azacitidine and venetoclax. Blood. 2025 Mar 20; 145(12):1237-1250.
-
Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma. Clin Cancer Res. 2025 Mar 17; 31(6):975-982.
-
Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes. Blood. 2025 Mar 13; 145(11):1126-1135.
-
Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium. Blood Adv. 2025 Mar 11; 9(5):1013-1023.
-
Long-term survival can be achieved in a significant fraction of older patients with core-binding factor acute myeloid leukemia treated with intensive chemotherapy. Haematologica. 2025 Mar 01; 110(3):608-620.
-
Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy. Blood Adv. 2025 Feb 25; 9(4):783-792.
-
A Unique Case of Gross Hematuria in a Patient With Ewing Sarcoma. J Pediatr Hematol Oncol. 2025 Apr 01; 47(3):140-143.
-
Vincristine Sulfate Liposome Injection With Combination Chemotherapy for Children, Adolescents, and Young Adults With Relapsed Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium Trial. Pediatr Blood Cancer. 2025 May; 72(5):e31584.
-
Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia. Blood Adv. 2025 Feb 11; 9(3):617-626.